Yuyu Pharma, Inc. (000227.KS)
KRW 9750.0
(-0.41%)
KRW 9750.0
(-0.41%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -7.18 Billion KRW | -62.27% |
| 2022 | -4.42 Billion KRW | -380.87% |
| 2021 | -920.28 Million KRW | -138.15% |
| 2020 | 2.41 Billion KRW | -48.91% |
| 2019 | 4.72 Billion KRW | 17.46% |
| 2018 | 4.02 Billion KRW | -11.48% |
| 2017 | 4.54 Billion KRW | -22.84% |
| 2016 | 5.88 Billion KRW | 2429.35% |
| 2015 | -252.67 Million KRW | 96.62% |
| 2014 | -7.46 Billion KRW | -497.94% |
| 2013 | 1.87 Billion KRW | -37.0% |
| 2012 | 2.97 Billion KRW | 56.22% |
| 2011 | 1.9 Billion KRW | 70.66% |
| 2010 | 1.11 Billion KRW | -50.85% |
| 2009 | 2.27 Billion KRW | 139.97% |
| 2008 | -5.68 Billion KRW | -141.92% |
| 2007 | 13.56 Billion KRW | 58.51% |
| 2006 | 8.55 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 1.24 Billion KRW | -76.02% |
| 2024 Q1 | 5.17 Billion KRW | 576.41% |
| 2023 Q1 | 458.16 Million KRW | 125.37% |
| 2023 Q2 | -3.45 Billion KRW | -855.03% |
| 2023 Q4 | -1.08 Billion KRW | 60.22% |
| 2023 FY | -7.18 Billion KRW | -62.27% |
| 2023 Q3 | -2.73 Billion KRW | 21.05% |
| 2022 Q2 | -889.99 Million KRW | -1120.32% |
| 2022 FY | -4.42 Billion KRW | -380.87% |
| 2022 Q4 | -1.8 Billion KRW | -9.05% |
| 2022 Q1 | -72.93 Million KRW | 95.83% |
| 2022 Q3 | -1.65 Billion KRW | -86.1% |
| 2021 FY | -920.28 Million KRW | -138.15% |
| 2021 Q1 | 277.3 Million KRW | 155.82% |
| 2021 Q2 | -157.6 Million KRW | -156.83% |
| 2021 Q3 | -586.24 Million KRW | -271.98% |
| 2021 Q4 | -1.74 Billion KRW | -198.04% |
| 2020 Q1 | 2.15 Billion KRW | 58.87% |
| 2020 Q3 | 683.41 Million KRW | 164.52% |
| 2020 Q4 | -496.77 Million KRW | -172.69% |
| 2020 FY | 2.41 Billion KRW | -48.91% |
| 2020 Q2 | -1.05 Billion KRW | -149.13% |
| 2019 Q1 | 1.25 Billion KRW | 46.15% |
| 2019 Q2 | 1.09 Billion KRW | -12.42% |
| 2019 FY | 4.72 Billion KRW | 17.46% |
| 2019 Q4 | 1.35 Billion KRW | 34.26% |
| 2019 Q3 | 1.01 Billion KRW | -8.03% |
| 2018 Q1 | 1.83 Billion KRW | 0.0% |
| 2018 FY | 4.02 Billion KRW | -11.48% |
| 2018 Q2 | 860.93 Million KRW | -53.1% |
| 2018 Q4 | 858.74 Million KRW | 84.87% |
| 2018 Q3 | 464.52 Million KRW | -46.04% |
| 2017 Q3 | 1.78 Billion KRW | 17.3% |
| 2017 Q1 | 1.67 Billion KRW | 5.15% |
| 2017 FY | 4.54 Billion KRW | -22.84% |
| 2017 Q2 | 1.52 Billion KRW | -9.15% |
| 2016 Q4 | 1.59 Billion KRW | -25.79% |
| 2016 Q1 | 235.43 Million KRW | -57.15% |
| 2016 FY | 5.88 Billion KRW | 2429.35% |
| 2016 Q3 | 2.15 Billion KRW | 372.1% |
| 2016 Q2 | 455.97 Million KRW | 93.67% |
| 2015 FY | -252.67 Million KRW | 96.62% |
| 2015 Q4 | 549.44 Million KRW | 274.94% |
| 2015 Q3 | -314.07 Million KRW | 56.59% |
| 2015 Q2 | -723.48 Million KRW | 90.76% |
| 2015 Q1 | -7.82 Billion KRW | -956.33% |
| 2014 Q3 | 805.72 Million KRW | 159.29% |
| 2014 FY | -7.46 Billion KRW | -497.94% |
| 2014 Q4 | 914.16 Million KRW | 13.46% |
| 2014 Q1 | 1.17 Billion KRW | 351.62% |
| 2014 Q2 | -1.35 Billion KRW | -215.71% |
| 2013 Q4 | 260.06 Million KRW | -19.78% |
| 2013 Q1 | 2.5 Billion KRW | 1242.93% |
| 2013 Q2 | 117.8 Million KRW | -95.29% |
| 2013 Q3 | 324.17 Million KRW | 175.17% |
| 2013 FY | 1.87 Billion KRW | -37.0% |
| 2012 Q3 | 83.97 Million KRW | -59.68% |
| 2012 Q4 | 186.18 Million KRW | 121.72% |
| 2012 FY | 2.97 Billion KRW | 56.22% |
| 2012 Q2 | 208.25 Million KRW | 0.0% |
| 2012 Q1 | - KRW | -100.0% |
| 2011 Q3 | 876.09 Million KRW | 113.75% |
| 2011 Q2 | 409.86 Million KRW | -62.98% |
| 2011 FY | 1.9 Billion KRW | 70.66% |
| 2011 Q1 | 1.1 Billion KRW | -32.15% |
| 2011 Q4 | 848.09 Million KRW | -3.2% |
| 2010 Q4 | 1.63 Billion KRW | 183.65% |
| 2010 Q3 | -1.95 Billion KRW | -693.07% |
| 2010 Q2 | 328.92 Million KRW | -94.13% |
| 2010 Q1 | 5.6 Billion KRW | 309.4% |
| 2010 FY | 1.11 Billion KRW | -50.85% |
| 2009 Q4 | 1.36 Billion KRW | 218.8% |
| 2009 Q3 | -1.15 Billion KRW | 67.53% |
| 2009 Q1 | -4.66 Billion KRW | -41.62% |
| 2009 Q2 | -3.55 Billion KRW | 23.85% |
| 2009 FY | 2.27 Billion KRW | 139.97% |
| 2008 Q1 | 435.85 Million KRW | -90.21% |
| 2008 FY | -5.68 Billion KRW | -141.92% |
| 2008 Q4 | -3.29 Billion KRW | -412.52% |
| 2008 Q3 | 1.05 Billion KRW | -13.36% |
| 2008 Q2 | 1.21 Billion KRW | 179.04% |
| 2007 FY | 13.56 Billion KRW | 58.51% |
| 2007 Q2 | 6.53 Billion KRW | 0.0% |
| 2007 Q3 | 2.14 Billion KRW | -67.2% |
| 2007 Q4 | 4.45 Billion KRW | 107.57% |
| 2006 FY | 8.55 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 112.383% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 87.949% |
| HANDOK Inc. | -28.79 Billion KRW | 75.064% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 14.667% |
| Yuhan Corporation | 93.5 Billion KRW | 107.679% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 164.562% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 71.059% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 104.911% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | 304.665% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -186.501% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | -246.249% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | -58.7% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 132.154% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -0.0% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 65.709% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | 300.395% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 93.928% |
| JW Holdings Corporation | 19.02 Billion KRW | 137.742% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 90.902% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 103.379% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 119.405% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 87.473% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 217.301% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | 531.664% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 243.482% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -0.0% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 119.426% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 106.44% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 119.405% |
| Yuhan Corporation | 93.5 Billion KRW | 107.679% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 55.809% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | -85.288% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 217.35% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 119.405% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 137.983% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 114.879% |
| CKD Bio Corp. | -24.19 Billion KRW | 70.318% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 130.024% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 126.171% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 124.118% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 87.473% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 115.276% |
| Boryung Corporation | 40.2 Billion KRW | 117.862% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 77.08% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -186.501% |
| JW Lifescience Corporation | 28.14 Billion KRW | 125.515% |